BIOTECanada Competitors

Molecular Devices is one of the world’s leading providers of high-performance life science technology. We make advanced scientific discovery possible for academia, pharma, and biotech customers with platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. From cancer to COVID-19, we've contributed to scientific breakthroughs described in over 230,000 peer-reviewed publications. Over 160,000 of our innovative solutions are incorporated into laboratories worldwide, enabling scientists to improve productivity and effectiveness – ultimately accelerating research and the development of new therapeutics. Molecular Devices is headquartered in Silicon Valley, Calif., with best-in-class teams around the globe. Over 1,000 associates are guided by our diverse leadership team and female president that prioritize a culture of collaboration, engagement, diversity, and inclusion. Molecular Devices is proud to be part of Danaher, a global life sciences and diagnostics innovator committed to accelerating the power of science and technology to improve human health. As part of Danaher, Molecular Devices is connected to a uniquely broad ecosystem of expertise, technologies, and capabilities. Together, we partner closely with customers to help solve their toughest challenges with greater speed and certainty. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. To learn more about how Molecular Devices helps fast-track scientific discovery, visit www.moleculardevices.com.

Zymeworks is a global biotechnology company developing and managing a portfolio of differentiated biotherapeutics to improve the standard of care for patients with difficult-to-treat cancers and autoimmune diseases. Leveraging our proprietary antibody engineering platforms, we are advancing a diverse pipeline of multispecific antibodies and antibody-drug conjugates, alongside partnered programs including Ziihera® (zanidatamab-hrii). Our integrated R&D engine and strategic partnerships enable the novel design of next-generation antibody therapeutics addressing significant unmet medical need.

Medicago develops vaccines and treatments to help fight emerging global health challenges, today and in the future. Please note that we may come across a situation not outlined above that will require the removal of your comment. Please know that Medicago reserves the right to delete any comment at its sole discretion. If you feel your comment has been unfairly removed, please contact us. For information about our commenting guidelines, please visit: http://ow.ly/6mKh50HKyUR Medicago développe des vaccins et des traitements pour répondre rapidement aux nouveaux défis de santé mondiaux. Medicago se réserve le droit de supprimer tout commentaire à sa seule discrétion. Si vous estimez que votre commentaire a été injustement retiré, veuillez communiquer avec nous. Pour plus d’information sur nos conditions d’utilisation, visitez notre page Nétiquette: http://ow.ly/vXuO50HKFSU